The DOI matches its Crossref record; 51 of the 51 references it cites were found in a registry or an index.
In vivo genome editing using Staphylococcus aureus Cas9
Open accessAbstract
The RNA-guided endonuclease Cas9 has emerged as a versatile genome-editing platform. However, the size of the commonly used Cas9 from Streptococcus pyogenes (SpCas9) limits its utility for basic research and therapeutic applications that use the highly versatile adeno-associated virus (AAV) delivery vehicle. Here, we characterize six smaller Cas9 orthologues and show that Cas9 from Staphylococcus aureus (SaCas9) can edit the genome with efficiencies similar to those of SpCas9, while being more than 1 kilobase shorter. We packaged SaCas9 and its single guide RNA expression cassette into a single AAV vector and targeted the cholesterol regulatory gene Pcsk9 in the mouse liver. Within one week of injection, we observed >40% gene modification, accompanied by significant reductions in serum Pcsk9 and total cholesterol levels. We further assess the genome-wide targeting specificity of SaCas9 and SpCas9 using BLESS, and demonstrate that SaCas9-mediated in vivo genome editing has the potential to be efficient and specific.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Also, the requirement of a specific PAM Sequence for targeted genome editing is crucial, and even though it reduces off-target activity, it often results in suboptimal DNA cleavage, editing efficiencies (Ran et al., 2015; Edraki et al., 2019) and restricting the scope of targeted edition.”
From Emerging applications of gene editing technologies for the development of climate-resilient crops (2025) · cites this paper as Ran et al., 2015
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Cas9 genomic localization is delimited by the protospacer adjacent motif (PAM), which is NGG for SpCas9 while evolved variants of SpCas9 tolerate a broader range of PAM sequences17–21.”
From One-step generation of tumor models by base editor multiplexing in adult stem cell-derived organoids (2023) · cites this paper as [20]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“The SpCas9 homolog derived from Staphylococcus aureus (SaCas9) has been extensively characterized as a highly efficient and significantly smaller alternative to SpCas9.”
From One-step generation of tumor models by base editor multiplexing in adult stem cell-derived organoids (2023) · cites this paper as [20]
The cited source says what the claim attributes to it.
In the citing paper
“It recognizes an NNGRRT PAM (where R = A or G)20.”
From One-step generation of tumor models by base editor multiplexing in adult stem cell-derived organoids (2023) · cites this paper as [20]
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Recent advancements in gene-editing technologies have led to the development of artificial Cas9 variants with relaxed PAM specificities, which improve efficiency but are associated with an increase in off-target effects and a decrease in target specificity (Ran et al., 2015).”
From Emerging applications of gene editing technologies for the development of climate-resilient crops (2025) · cites this paper as Ran et al., 2015
Experimental — accuracy not yet measured
In the citing paper
“Recently, a smaller form of Cas9 was developed, and shown capable of packing and delivery with sgRNA by AAV in vivo12.”
From Therapeutic genome editing by combined viral and non-viral delivery of CRISPR system components in vivo (2016) · cites this paper as [12]
In the citing paper
“Adenovirus or adeno-associated virus (AAV)-mediated CRISPR-Cas9 delivery has been successfully applied to knockout genes in the mouse brain and liver12,13.”
From Therapeutic genome editing by combined viral and non-viral delivery of CRISPR system components in vivo (2016) · cites this paper as [12]
In the citing paper
“A smaller form of Cas9 (Staphylococcus aureus Cas9), which fits into AAV vectors, has been recently used to knockout genes by NHEJ in the mouse liver. More than 40% indel formations in Pcsk9 locus was reported12.”
From Therapeutic genome editing by combined viral and non-viral delivery of CRISPR system components in vivo (2016) · cites this paper as [12]
In the citing paper
“For example, less than 10% indels at the Apob locus in the mouse liver was reported in the same study12.”
From Therapeutic genome editing by combined viral and non-viral delivery of CRISPR system components in vivo (2016) · cites this paper as [12]
In the citing paper
“However, the large genetic size of Cas9 (~ 4.5 kb) and the total plasmid size (> 7 kb) significantly increase the difficulty of delivery and expression of CRISPR/Cas9 systems [94].”
From Non-viral delivery systems for CRISPR/Cas9-based genome editing: challenges and opportunities (2018) · cites this paper as [94]
In the citing paper
“Although the newly discovered Cas9 form from Staphylococcus aureus strain (SaCas9) is about 1 kb shorter than SpCas9, the overall genetic size is still too large for application [94, 140].”
From Non-viral delivery systems for CRISPR/Cas9-based genome editing: challenges and opportunities (2018) · cites this paper as [94]
In the citing paper
“The Cas9 from Staphylococcus aureus (SaCas9) is over 1 kb shorter (3.15 kb) than SpCas9 [69].”
From Viral Delivery Systems for CRISPR (2019) · cites this paper as [69]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Model-based Analysis of ChIP-Seq (MACS)
Zhang, Y., Liu, T., Meyer, C. A., Eeckhoute, J., Johnson, D. S., Bernstein, B. E., Nusbaum, C., Myers, R. M., Brown, M., Li, W., et al. (2008) · Genome Biology · doi:10.1186/gb-2008-9-9-r137 · Cited by 18,386
A Programmable Dual-RNA–Guided DNA Endonuclease in Adaptive Bacterial Immunity
Jinek, M., Chylinski, K., Fonfara, I., Hauer, M., Doudna, J. A., & Charpentier, E. (2012) · Science · doi:10.1126/science.1225829 · Cited by 17,116
Multiplex Genome Engineering Using CRISPR/Cas Systems
Cong, L., Ran, F. A., Cox, D., Lin, S., Barretto, R., Habib, N., Hsu, P. D., Wu, X., Jiang, W., Marraffini, L. A., et al. (2013) · Science · doi:10.1126/science.1231143 · Cited by 15,339
Self-citationMfold web server for nucleic acid folding and hybridization prediction
Zuker, M. (2003) · Nucleic Acids Research · doi:10.1093/nar/gkg595 · Cited by 13,404
WebLogo: A Sequence Logo Generator: Figure 1Preprint
Crooks, G. E., Hon, G. C., Chandonia, J., & Brenner, S. E. (2004) · Genome Research · doi:10.1101/gr.849004 · Cited by 12,480
RNA-Guided Human Genome Engineering via Cas9
Mali, P., Yang, L., Esvelt, K. M., Aach, J., Guell, M., DiCarlo, J. E., Norville, J. E., & Church, G. M. (2013) · Science · doi:10.1126/science.1232033 · Cited by 9,210
CRISPR Provides Acquired Resistance Against Viruses in Prokaryotes
Barrangou, R., Fremaux, C., Deveau, H., Richards, M., Boyaval, P., Moineau, S., Romero, D. A., & Horvath, P. (2007) · Science · doi:10.1126/science.1138140 · Cited by 5,947
Development and Applications of CRISPR-Cas9 for Genome Engineering
Hsu, P. D., Lander, E. S., & Zhang, F. (2014) · Cell · doi:10.1016/j.cell.2014.05.010 · Cited by 5,762
Self-citationDNA targeting specificity of RNA-guided Cas9 nucleases
Hsu, P. D., Scott, D. A., Weinstein, J. A., Ran, F. A., Konermann, S., Agarwala, V., Li, Y., Fine, E. J., Wu, X., Shalem, O., et al. (2013) · Nature Biotechnology · doi:10.1038/nbt.2647 · Cited by 4,741
Self-citationHigh-Frequency off-Target Mutagenesis Induced by CRISPR-Cas Nucleases in Human Cells
Fu, Y., Foden, J. A., Khayter, C., Maeder, M. L., Reyon, D., Joung, J. K., & Sander, J. D. (2013) · Nature Biotechnology · doi:10.1038/nbt.2623 · Cited by 3,292
Cited by
Sorted by citations
Items 901–1,000 of 1,009
The Impact of HIV-1 Genetic Diversity on CRISPR-Cas9 Antiviral Activity and Viral Escape
Darcis, G., Binda, C. S., Klaver, B., Herrera-Carrillo, E., Berkhout, B., & Das, A. T. (2019) · Viruses · doi:10.3390/v11030255 · Cited by 45
Elimination of infectious HIV DNA by CRISPR–Cas9
Das, A. T., Binda, C. S., & Berkhout, B. (2019) · Current Opinion in Virology · doi:10.1016/j.coviro.2019.07.001 · Cited by 44
Zhang, W., & Matlashewski, G. (2019) · mSphere · doi:10.1128/msphere.00408-19 · Cited by 44
Delivery of CRISPR-Cas9 system for screening and editing RNA binding proteins in cancer
Yan, J., Kang, D. D., Turnbull, G., & Dong, Y. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.114042 · Cited by 45
Emerging applications of gene editing technologies for the development of climate-resilient crops
Chavhan, R. L., Jaybhaye, S. G., Hinge, V. R., Deshmukh, A. S., Shaikh, U. S., Jadhav, P. K., Kadam, U. S., & Hong, J. C. (2025) · Frontiers in Genome Editing · doi:10.3389/fgeed.2025.1524767 · Cited by 55
Off-target effects of base editors: what we know and how we can reduce it
Slesarenko, Y. S., Лавров, А. В., & Smirnikhina, S. (2021) · Current Genetics · doi:10.1007/s00294-021-01211-1 · Cited by 45
May, D., Paldi, K., & Altpeter, F. (2023) · The Plant Genome · doi:10.1002/tpg2.20298 · Cited by 47
Song, M. (2017) · Biotechnology Progress · doi:10.1002/btpr.2484 · Cited by 46
Raikwar, S. P., Kikkeri, N. S., Sakuru, R. C., Saeed, D., Zahoor, H., Premkumar, K., Mentor, S., Thangavel, R., Dubova, I., Ahmed, M. E., et al. (2019) · Journal of Neuroimmune Pharmacology · doi:10.1007/s11481-019-09849-y · Cited by 48
Genome Editing for Mucopolysaccharidoses
Poletto, É., Baldo, G., & Gomez‐Ospina, N. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21020500 · Cited by 45
Rational Selection of CRISPR-Cas9 Guide RNAs for Homology-Directed Genome Editing
Tatiossian, K. J., Clark, R. D. E., Huang, C., Thornton, M. E., Grubbs, B. H., & Cannon, P. M. (2020) · Molecular Therapy · doi:10.1016/j.ymthe.2020.10.006 · Cited by 40
Structure of the type V-C CRISPR-Cas effector enzyme
Kurihara, N., Nakagawa, R., Hirano, H., Okazaki, S., Tomita, A., Kobayashi, K., Kusakizako, T., Nishizawa, T., Yamashita, K., Scott, D. A., et al. (2022) · Molecular Cell · doi:10.1016/j.molcel.2022.03.006 · Cited by 42
Self-citationWheat genome editing expedited by efficient transformation techniques: Progress and perspectives
Wang, K., Riaz, B., & Ye, X. (2017) · The Crop Journal · doi:10.1016/j.cj.2017.09.009 · Cited by 45
Massively targeted evaluation of therapeutic CRISPR off-targets in cells
Pan, X., Qu, K., Yuan, H., Xiang, X., Anthon, C., Pashkova, L., Liang, X., Han, P., Corsi, G. I., Xu, F., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-31543-6 · Cited by 42
Conti, G., Xoconostle‐Cázares, B., Marcelino-Pérez, G., Hopp, H. E., & Reyes, C. A. (2021) · Frontiers in Plant Science · doi:10.3389/fpls.2021.768197 · Cited by 42
Genome engineering: Drosophila melanogaster and beyond
Venken, K. J. T., Sarrion‐Perdigones, A., Vandeventer, P. J., Abel, N. S., Christiansen, A. E., & Hoffman, K. L. (2015) · Wiley Interdisciplinary Reviews Developmental Biology · doi:10.1002/wdev.214 · Cited by 43
Using CRISPR/Cas to study gene function and model disease in vivo
Tschaharganeh, D. F., Lowe, S. W., Garippa, R. J., & Livshits, G. (2016) · FEBS Journal · doi:10.1111/febs.13750 · Cited by 47
Stem cell-based therapies for HIV/AIDS
Pernet, O., Yadav, S. S., & An, D. S. (2016) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2016.04.027 · Cited by 44
Williams, M. R., Fricano-Kugler, C. J., Getz, S. A., Skelton, P. D., Lee, J., Rizzuto, C. P., Geller, J. S., Li, M., & Luikart, B. W. (2016) · Scientific Reports · doi:10.1038/srep25611 · Cited by 46
CRISPR-Mediated Epigenome Editing.
Enríquez, P. (2016) · Europe PMC (PubMed Central) · Cited by 41
CRISPR/Cas9-mediated correction of human genetic disease
Men, K., Duan, X., He, Z., Yang, Y., Yao, S., & Wei, Y. (2017) · Science China Life Sciences · doi:10.1007/s11427-017-9032-4 · Cited by 44
Luo, W., Galvan, D. L., Woodard, L. E., Dorset, D. C., Levy, S. A., & Wilson, M. H. (2017) · Nucleic Acids Research · doi:10.1093/nar/gkx572 · Cited by 42
Personalised genome editing – The future for corneal dystrophies
Moore, T., Christie, K. A., Marshall, J., & Nesbit, M. A. (2018) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2018.01.004 · Cited by 44
Yamamoto, A., Ishida, T., Yoshimura, M., Kimura, Y., & Sawa, S. (2019) · Plant and Cell Physiology · doi:10.1093/pcp/pcz118 · Cited by 42
Herpesviral lytic gene functions render the viral genome susceptible to novel editing by CRISPR/Cas9
Oh, H. S., Neuhausser, W., Eggan, P., Angelova, M., Kirchner, R. D., Eggan, K. C., & Knipe, D. M. (2019) · eLife · doi:10.7554/elife.51662 · Cited by 42
Engineering Stable Pseudomonas putida S12 by CRISPR for 2,5-Furandicarboxylic Acid (FDCA) Production
Pham, N. N., Chen, C.-Y., Li, H., Nguyen, M. T. T., Nguyen, P. K. P., Tsai, S., Chou, J.-Y., Ramli, T. C., & Hu, Y. (2020) · ACS Synthetic Biology · doi:10.1021/acssynbio.0c00006 · Cited by 42
Gene therapy for Fabry disease: Progress, challenges, and outlooks on gene-editing
Domm, J. M., Wootton, S. K., Medin, J. A., & West, M. L. (2021) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2021.07.006 · Cited by 45
Rational design of a compact CRISPR-Cas9 activator for AAV-mediated delivery
Vora, S., Cheng, J., Xiao, R., VanDusen, N. J., Quintino, L., Pu, W. T., Vandenberghe, L. H., Chavez, A., & Church, G. (2018) · doi:10.1101/298620 · Cited by 42
Improved prime editors enable pathogenic allele correction and cancer modelling in adult micePreprint
Liu, P., Liang, S., Zheng, C., Mintzer, E., Zhao, Y. G., Ponnienselvan, K., Mir, A., Sontheimer, E. J., Gao, G., Flotte, T. R., et al. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.12.15.422970 · Cited by 42
Targeting cholesterol metabolism in Cancer: From molecular mechanisms to therapeutic implications
Lu, J., Chen, S., Bai, X., Liao, M., Qiu, Y., Zheng, L., & Yu, H. (2023) · Biochemical Pharmacology · doi:10.1016/j.bcp.2023.115907 · Cited by 44
Minimizing off-Target Mutagenesis Risks Caused by Programmable Nucleases
Ishida, K., Gee, P., & Hotta, A. (2015) · International Journal of Molecular Sciences · doi:10.3390/ijms161024751 · Cited by 41
Jamal, M., Khan, F. A., Lin, D., Habib, Z., Dai, J., & Cao, G. (2016) · Current Issues in Molecular Biology · doi:10.21775/cimb.020.001 · Cited by 41
Sato, M., Ohtsuka, M., Watanabe, S., & Gurumurthy, C. B. (2016) · Biology Direct · doi:10.1186/s13062-016-0115-8 · Cited by 41
Rubio, A., Luoni, M., Giannelli, S. G., Radice, I., Iannielli, A., Cancellieri, C., Berardino, C. D., Regalia, G., Lazzari, G., Menegon, A., et al. (2016) · Scientific Reports · doi:10.1038/srep37540 · Cited by 41
CRISPR/Cas9- loxP -Mediated Gene Editing as a Novel Site-Specific Genetic Manipulation Tool
Yang, F., Liu, C., Chen, D., Tu, M., Xie, H., Sun, H., Ge, X., Tang, L., Li, J., Zheng, J., et al. (2017) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2017.04.018 · Cited by 44
CRISPR/Cas9: at the cutting edge of hepatology
Pankowicz, F. P., Jarrett, K. E., Lagor, W. R., & Bissig, K. (2017) · Gut · doi:10.1136/gutjnl-2016-313565 · Cited by 43
GUIDEseq: a bioconductor package to analyze GUIDE-Seq datasets for CRISPR-Cas nucleases
Zhu, L. J., Lawrence, M., Gupta, A., Pagès, H., Küçükural, A., Garber, M. G., & Wolfe, S. A. (2017) · BMC Genomics · doi:10.1186/s12864-017-3746-y · Cited by 42
Improved Lentiviral Gene Delivery to Mouse Liver by Hydrodynamic Vector Injection through Tail Vein
Dalsgaard, T. K., Cecchi, C. R., Askou, A. L., Bak, R. O., Andersen, P. O., HOUGAARD, D. M., Jensen, T. G., Dagnæs‐Hansen, F., Mikkelsen, J. G., Corydon, T. J., et al. (2018) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2018.07.005 · Cited by 41
Luan, B., Xu, G., Feng, M., Cong, L., & Zhou, R. (2019) · Journal of the American Chemical Society · doi:10.1021/jacs.8b13144 · Cited by 42
Self-citationCRISPR-Switch regulates sgRNA activity by Cre recombination for sequential editing of two loci
Chylinski, K., Hubmann, M., Hanna, R. E., Yanchus, C., Michlits, G., Uijttewaal, E. C. H., Doench, J. G., Schramek, D., & Elling, U. (2019) · Nature Communications · doi:10.1038/s41467-019-13403-y · Cited by 40
Therapeutic genome editing in cardiovascular diseases
Nishiga, M., Qi, L. S., & Wu, J. C. (2020) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.02.003 · Cited by 42
CRISPR-based strategies for targeted transgene knock-in and gene correction
Lau, C., Tin, C., & Suh, Y. (2020) · Faculty Reviews · doi:10.12703/r/9-20 · Cited by 46
Tickner, Z. J., & Farzan, M. (2021) · Pharmaceuticals · doi:10.3390/ph14060554 · Cited by 40
Loesch, R., Caruso, S., Paradis, V., Godard, C., Gougèlet, A., Renault, G., Picard, S., Tanaka, I., Renoux-Martin, Y., Perret, C., et al. (2021) · Journal of Hepatology · doi:10.1016/j.jhep.2022.02.023 · Cited by 46
Myotonic Dystrophy and Developmental Regulation of RNA Processing
Thomas, J. D., Oliveira, R., Sznajder, Ł. J., & Swanson, M. S. (2018) · Comprehensive physiology · doi:10.1002/cphy.c170002 · Cited by 51
The AAV-mediated and RNA-guided CRISPR/Cas9 system for gene therapy of DMD and BMD
Wang, J.-Z., Wu, P., Shi, Z.-M., Xu, Y.-L., & Liu, Z.-J. (2017) · Brain and Development · doi:10.1016/j.braindev.2017.03.024 · Cited by 41
Xiong, X., Li, Z., Liang, J., Liu, K., Li, C., & Li, J.-F. (2022) · Nucleic Acids Research · doi:10.1093/nar/gkac166 · Cited by 41
Thean, D., Chu, H. Y., Fong, J. H. C., Chan, B. K. C., Zhou, P., Kwok, C. C. S., Chan, Y. M., Mak, S. Y. L., Choi, G. C. G., Ho, J. W. K., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-29874-5 · Cited by 44
Wolff, J. H., & Mikkelsen, J. G. (2022) · Journal of Biomedical Science · doi:10.1186/s12929-022-00865-4 · Cited by 47
Translating musculoskeletal bioengineering into tissue regeneration therapies
Khodabukus, A., Guyer, T., Moore, A. C., Stevens, M. M., Guldberg, R. E., & Bursac, N. (2022) · Science Translational Medicine · doi:10.1126/scitranslmed.abn9074 · Cited by 40
He, X., Zhang, Z., Xue, J., Wang, Y., Zhang, S., Wei, J., Zhang, C., Wang, J., Urip, B. A., Ngan, C. C., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-34898-y · Cited by 43
Negative DNA supercoiling induces genome-wide Cas9 off-target activity
Newton, M. D., Losito, M., Smith, Q. M., Parnandi, N., Taylor, B. J., Akçakaya, P., Maresca, M., van Eijk, P., Reed, S. H., Boulton, S. J., et al. (2023) · Molecular Cell · doi:10.1016/j.molcel.2023.09.008 · Cited by 41
Engineering IscB to develop highly efficient miniature editing tools in mammalian cells and embryos
Xue, N., Hong, D., Zhang, D., Wang, Q., Zhang, S., Yang, L., Chen, X., Li, Y., Han, H., Hu, C., et al. (2024) · Molecular Cell · doi:10.1016/j.molcel.2024.07.007 · Cited by 45
CRISPRoffT: comprehensive database of CRISPR/Cas off-targets
Wang, G., Liu, X., Wang, A., Wen, J., Kim, P., Song, Q., Liu, X., & Zhou, X. (2024) · Nucleic Acids Research · doi:10.1093/nar/gkae1025 · Cited by 42
Engineering synthetic phosphorylation signaling networks in human cells
Yang, X., Rocks, J. W., Jiang, K., Walters, A. J., Rai, K., Liu, J., Nguyen, J., Olson, S. D., Mehta, P., Collins, J. J., et al. (2025) · Science · doi:10.1126/science.adm8485 · Cited by 41
Alariqi, M., Ramadan, M., Yu, L., Hui, F., Hussain, A., Zhou, X., Yu, Y., Zhang, X., & Jin, S. (2025) · Advanced Science · doi:10.1002/advs.202416331 · Cited by 42
Ma, S., Liu, Y., Liu, Y., Chang, J., Zhang, T., Wang, X., Shi, R., Lü, W., Xia, X., Zhao, P., et al. (2017) · Insect Biochemistry and Molecular Biology · doi:10.1016/j.ibmb.2017.02.003 · Cited by 40
Advanced editing of the nuclear and plastid genomes in plants
Piatek, A., Lenaghan, S. C., & Stewart, C. N. (2018) · Plant Science · doi:10.1016/j.plantsci.2018.02.025 · Cited by 40
Koeppel, I., Hertig, C. W., Hoffie, R. E., & Kumlehn, J. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20112647 · Cited by 46
Wide Horizons of CRISPR-Cas-Derived Technologies for Basic Biology, Agriculture, and Medicine
Molla, K. A., Karmakar, S., & Islam, T. (2020) · Springer protocols handbooks/Springer protocols · doi:10.1007/978-1-0716-0616-2_1 · Cited by 42
Kim, D., Kang, B., & Kim, J. (2021) · Nature Protocols · doi:10.1038/s41596-020-00453-6 · Cited by 44
Katzmann, J. L., Cupido, A. J., & Laufs, U. (2022) · Metabolites · doi:10.3390/metabo12010070 · Cited by 41
Wang, Y., Tang, Y. X., Zhao, X., Huang, G., Gong, J., Yang, S.-D., Li, H. Z., Wan, W., Jia, C., Chen, G., et al. (2022) · Acta Biomaterialia · doi:10.1016/j.actbio.2022.09.046 · Cited by 42
Recent Advancements in DNA Damage–Transcription Crosstalk and High-Resolution Mapping of DNA Breaks
Vitelli, V., Galbiati, A., Iannelli, F., Pessina, F., Sharma, S., & di Fagagna, F. D. (2017) · Annual Review of Genomics and Human Genetics · doi:10.1146/annurev-genom-091416-035314 · Cited by 41
A most formidable arsenal: genetic technologies for building a better mousePreprint
Clark, J. F., Dinsmore, C. J., & Soriano, P. M. (2020) · Genes & Development · doi:10.1101/gad.342089.120 · Cited by 40
Paving the way towards precise and safe CRISPR genome editing
Śledziński, P., Dabrowska, M., Nowaczyk, M., & Olejniczak, M. (2021) · Biotechnology Advances · doi:10.1016/j.biotechadv.2021.107737 · Cited by 43
Using Xenopus to study genetic kidney diseases
Lienkamp, S. S. (2016) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2016.02.002 · Cited by 39
Tycko, J., Barrera, L. A., Huston, N. C., Friedland, A. E., Wu, X., Gootenberg, J. S., Abudayyeh, O. O., Myer, V. E., Wilson, C. J., & Hsu, P. D. (2018) · Nature Communications · doi:10.1038/s41467-018-05391-2 · Cited by 38
Self-citationPlasmodium falciparum In Vitro Drug Resistance Selections and Gene Editing
Ng, C. L., & Fidock, D. A. (2019) · Methods in molecular biology · doi:10.1007/978-1-4939-9550-9_9 · Cited by 39
CRISPR/Cas9-targeted removal of unwanted sequences from small-RNA sequencing libraries
Hardigan, A. A., Roberts, B. S., Moore, D. E., Ramaker, R. C., Jones, A. L., & Myers, R. M. (2019) · Nucleic Acids Research · doi:10.1093/nar/gkz425 · Cited by 37
Multiple Origins and Specific Evolution of CRISPR/Cas9 Systems in Minimal Bacteria (Mollicutes)
Ipoutcha, T., Τsarmpopoulos, Ι., Talenton, V., Gaspin, C., Moisan, A., Walker, C. A., Brownlie, J., Blanchard, A., Thébault, P., & Sirand‐Pugnet, P. (2019) · Frontiers in Microbiology · doi:10.3389/fmicb.2019.02701 · Cited by 41
CRISPR/Cas Derivatives as Novel Gene Modulating Tools: Possibilities and In Vivo Applications
Xu, X., Hulshoff, M. S., Tan, X., Zeisberg, M., & Zeisberg, E. M. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21093038 · Cited by 41
Erwood, S., Laselva, O., Bily, T. M. I., Brewer, R. A., Rutherford, A. H., Bear, C. E., & Ivakine, E. A. (2020) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2020.05.002 · Cited by 40
Immunity to Cas9 as an Obstacle to Persistent Genome Editing
Gough, V., & Gersbach, C. A. (2020) · Molecular Therapy · doi:10.1016/j.ymthe.2020.05.007 · Cited by 41
A Tale of Two Moieties: Rapidly Evolving CRISPR/Cas-Based Genome Editing
Yang, L. C., & Chen, J. (2020) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2020.06.003 · Cited by 38
Padayachee, J., & Singh, M. (2020) · Nanobiomedicine · doi:10.1177/1849543520983196 · Cited by 39
Gene Therapy for Mucopolysaccharidosis Type II—A Review of the Current Possibilities
Zapolnik, P., & Pyrkosz, A. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22115490 · Cited by 39
Desgranges, E., Marzi, S., Moreau, K., Romby, P., & Caldelari, I. (2019) · Microbiology Spectrum · doi:10.1128/microbiolspec.gpp3-0038-2018 · Cited by 46
Precision targeting tumor cells using cancer-specific InDel mutations with CRISPR-Cas9
Kwon, T., Ra, J. S., Lee, S., Baek, I., Khim, K. W., Lee, E. A., Song, E. K., Otarbayev, D., Jung, W., Park, Y. H., et al. (2022) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2103532119 · Cited by 40
Engineered Campylobacter jejuni Cas9 variant with enhanced activity and broader targeting range
Nakagawa, R., Ishiguro, S., Okazaki, S., Mori, H., Tanaka, M., Aburatani, H., Yachie, N., Nishimasu, H., & Nureki, O. (2022) · Communications Biology · doi:10.1038/s42003-022-03149-7 · Cited by 42
Application and development of genome editing technologies to the Solanaceae plants
Yamamoto, T., Kashojiya, S., Kamimura, S., Kameyama, T., Ariizumi, T., Ezura, H., & Miura, K. (2018) · Plant Physiology and Biochemistry · doi:10.1016/j.plaphy.2018.02.019 · Cited by 40
Myoediting: Toward Prevention of Muscular Dystrophy by Therapeutic Genome Editing
Zhang, Y., Long, C., Bassel‐Duby, R., & Olson, E. N. (2018) · Physiological Reviews · doi:10.1152/physrev.00046.2017 · Cited by 42
Reprogramming the anti-tumor immune response via CRISPR genetic and epigenetic editing
Alves, E., Taifour, S., Dolcetti, R., Chee, J., Nowak, A. K., Gaudieri, S., & Blancafort, P. (2021) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2021.04.009 · Cited by 40
Focused ultrasound–mediated brain genome editing
Lao, Y., Ji, R., Zhou, J. K., Snow, K. J., Kwon, N., Saville, E., He, S., Chauhan, S., Chi, C., Datta, M. S., et al. (2023) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2302910120 · Cited by 38
Triple-negative breast tumors are dependent on mutant p53 for growth and survival
Dibra, D., Moyer, S. M., El‐Naggar, A. K., Qi, Y., Su, X., & Lozano, G. (2023) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2308807120 · Cited by 39
Shariati, L., Esmaeili, Y., Rahimmanesh, I., Babolmorad, S., Ziaei, G., Hasan, A., Boshtam, M., & Makvandi, P. (2023) · Environmental Research · doi:10.1016/j.envres.2023.116933 · Cited by 41
CRISPR/Cas9 system: recent applications in immuno-oncology and cancer immunotherapy
Chen, C., Wang, Z., & Qin, Y. (2023) · Experimental Hematology and Oncology · doi:10.1186/s40164-023-00457-4 · Cited by 42
Shen, Q., Ruan, H., Zhang, H., Wu, T., Zhu, K., Han, W., Dong, R., Ming, T., Qi, H., & Zhang, Y. (2024) · Frontiers in Microbiology · doi:10.3389/fmicb.2024.1375120 · Cited by 38
Kantor, B., O’Donovan, B., Rittiner, J. E., Hodgson, D., Lindner, N., Guerrero, S., Dong, W., Zhang, A., & Chiba‐Falek, O. (2024) · Nature Communications · doi:10.1038/s41467-024-50515-6 · Cited by 48
Application of CRISPR/Cas9 Technology to HBV
Lin, G., Zhang, K., & Li, J. (2015) · International Journal of Molecular Sciences · doi:10.3390/ijms161125950 · Cited by 41
CT-Finder: A Web Service for CRISPR Optimal Target Prediction and Visualization
Zhu, H., Misel, L., Graham, M., Robinson, M. L., & Liang, C. (2016) · Scientific Reports · doi:10.1038/srep25516 · Cited by 38
Genome-editing technologies for gene correction of hemophilia
Park, C., Lee, D. R., Sung, J. J., & Kim, D. (2016) · Human Genetics · doi:10.1007/s00439-016-1699-x · Cited by 39
Diving into marine genomics with CRISPR/Cas9 systems
Momose, T., & Concordet, J. (2016) · Marine Genomics · doi:10.1016/j.margen.2016.10.003 · Cited by 40
Musunuru, K. (2017) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2017.10.002 · Cited by 38
Engineering Point Mutant and Epitope‐Tagged Alleles in Mice Using Cas9 RNA‐Guided Nuclease
Gertsenstein, M., & Nutter, L. M. J. (2018) · Current Protocols in Mouse Biology · doi:10.1002/cpmo.40 · Cited by 41
A Single H1 Promoter Can Drive Both Guide RNA and Endonuclease Expression in the CRISPR-Cas9 System
Gao, Z., Herrera-Carrillo, E., & Berkhout, B. (2018) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2018.10.016 · Cited by 38
AAV-Mediated Gene Delivery to the Liver: Overview of Current Technologies and Methods
Palaschak, B., Herzog, R. W., & Markusic, D. M. (2019) · Methods in molecular biology · doi:10.1007/978-1-4939-9139-6_20 · Cited by 37
Progress and challenges in development of new therapies for urea cycle disorders
Soria, L. R., Mew, N. A., & Brunetti‐Pierri, N. (2019) · Human Molecular Genetics · doi:10.1093/hmg/ddz140 · Cited by 38
On the expression of recombinant Cas9 protein in E. coli BL21(DE3) and BL21(DE3) Rosetta strains
Carmignotto, G. P., & Azzoni, A. R. (2019) · Journal of Biotechnology · doi:10.1016/j.jbiotec.2019.09.012 · Cited by 38
Heat-Triggered Remote Control of CRISPR-dCas9 for Tunable Transcriptional Modulation
Gamboa, L., Phung, E. V., Li, H., Meyers, J. P., Hart, A. C., Miller, I. C., & Kwong, G. A. (2020) · ACS Chemical Biology · doi:10.1021/acschembio.9b01005 · Cited by 36
Metadata
- Authors
- Ran, F. A., Cong, L., Yan, W. X., Scott, D. A., Gootenberg, J. S., Kriz, A. J., Zetsche, B., Shalem, O., Wu, X., Makarova, K. S., Koonin, E. V., Sharp, P. A., & Zhang, F.
- Affiliations
- Broad Institute (US)
- Massachusetts Institute of Technology (US)
- Koch Institute for Integrative Cancer Research At MIT (US)
- National Institutes of Health (US)
- Corresponding author
- Zhang, Feng
- ORCID
- Venue
- Nature
- Published
- 2015-04
- Volume
- 520
- Issue
- 7546
- Pages
- 186-191
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- PMC
- PMC4393360
- OpenAlex
- W2070614858
- Cited by
- 2,687
- References
- 51
- Citations by year
- 2026: 126 · 2025: 167 · 2024: 180 · 2023: 199 · 2022: 285 · 2021: 263 · 2020: 274 · 2019: 261 · 2018: 264 · 2017: 288 · 2016: 264 · 2015: 113
- FWCI
- 134.53
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Digital Access to Scholarship at Harvard (DASH) (Harvard University) (submittedVersion, cc-by)
- RePEc: Research Papers in Economics (submittedVersion)
- DSpace@MIT (Massachusetts Institute of Technology) (submittedVersion, cc-by-nc)
- PMC
- Funders
- Howard Hughes Medical Institute
- National Institute of Mental Health (DP1MH100706)
- National Eye Institute (R01EY024259, P30EY012196)
- National Cancer Institute (R01CA133404, P01CA042063, P30CA014051, P30-CA-14051, P01 CA 42063)
- National Institute of General Medical Sciences (R01GM034277, T32GM008313, R01 GM34277, T32GM007753)
- National Institute of Diabetes and Digestive and Kidney Diseases (R01DK097768)
- National Center for Chronic Disease Prevention and Health Promotion (5DP1-MH100706)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › CRISPR and Genetic Engineering
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Keywords
- SaCas9, SpCas9, CRISPR/Cas9, in vivo gene editing, adeno-associated virus delivery, PCSK9, cholesterol regulation, targeting specificity, single guide RNA
- MeSH terms
- Proprotein Convertase 9, Animals, Base Sequence, Cholesterol, Genetic Engineering, Liver, Male, Mice, Inbred C57BL, Serine Endopeptidases, Staphylococcus aureus, Substrate Specificity, Genome, Gene Targeting, Proprotein Convertases, Mice, CRISPR-Associated Proteins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
